Plain-English translation of NCT07747324 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is a small, early-stage trial testing , a plant-based medicine used traditionally in South America, in patients with psychogenic non-epileptic seizures (seizures caused by stress or trauma, not by abnormal brain electrical activity). Researchers will give participants a single dose of the medication and monitor how it affects their seizures and overall well-being.
Psychogenic non-epileptic seizures can be very difficult to treat with standard medications, and many patients continue to suffer despite current therapies. This trial explores whether this medication might help by addressing the psychological roots of these seizures.
You likely qualify if…
You likely don't qualify if…
You will first gradually reduce and stop any psychiatric medications you are currently taking (under medical supervision) to avoid interactions with the study medication. On the study day, you will receive a single oral dose of based on your body weight. Researchers will monitor you closely during and after the dose to assess how the medication affects your seizures and any side effects.
AI-generated summary from trial data · Aug 6, 2026 · Not medical advice
Brazil
Phase
Safety & dosing / Early efficacy
Sponsor
University of Sao Paulo
Enrollment target
~15 participants
Started
July 2026
Primary completion
August 2027
Age range
18 Years – 60 Years
Last updated on clinicaltrials.gov in August 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.